988 related articles for article (PubMed ID: 25029122)
21. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
22. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases.
Hull D; Ma J; Singh H; Hossain D; Qian J; Bostwick DG
BJU Int; 2009 Oct; 104(7):915-8. PubMed ID: 19388995
[TBL] [Abstract][Full Text] [Related]
23. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.
Mohanty SK; Smith SC; Chang E; Luthringer DJ; Gown AM; Aron M; Amin MB
Am J Clin Pathol; 2014 Aug; 142(2):173-83. PubMed ID: 25015857
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.
Browne TJ; Hirsch MS; Brodsky G; Welch WR; Loda MF; Rubin MA
Hum Pathol; 2004 Dec; 35(12):1462-8. PubMed ID: 15619204
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
27. Immunocytochemical study of urine cytological preparations from secondary prostatic adenocarcinoma involving the urinary bladder.
Mai KT; Ahmed I; Robertson SJ; Belanger EC; Veinot JP; Islam S
Diagn Cytopathol; 2008 Oct; 36(10):715-20. PubMed ID: 18773445
[TBL] [Abstract][Full Text] [Related]
28. Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features.
Lane Z; Epstein JI; Ayub S; Netto GJ
Hum Pathol; 2008 Apr; 39(4):543-9. PubMed ID: 18234278
[TBL] [Abstract][Full Text] [Related]
29. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
30. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.
Oh WJ; Chung AM; Kim JS; Han JH; Hong SH; Lee JY; Choi YJ
J Pathol Transl Med; 2016 Sep; 50(5):345-54. PubMed ID: 27498545
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
32. Is atypical adenomatous hyperplasia of the prostate a precursor lesion?
Zhang C; Montironi R; MacLennan GT; Lopez-Beltran A; Li Y; Tan PH; Wang M; Zhang S; Iczkowski KA; Cheng L
Prostate; 2011 Dec; 71(16):1746-51. PubMed ID: 21480308
[TBL] [Abstract][Full Text] [Related]
33. Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.
Stewart J; Fleshner N; Cole H; Sweet J
J Clin Pathol; 2007 Jul; 60(7):773-80. PubMed ID: 16916997
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic utility of p63 and α-methyl acyl Co A racemase in resolving suspicious foci in prostatic needle biopsy and transurethral resection of prostate specimens.
Singh V; Manu V; Malik A; Dutta V; Mani NS; Patrikar S
J Cancer Res Ther; 2014; 10(3):686-92. PubMed ID: 25313761
[TBL] [Abstract][Full Text] [Related]
35. The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers.
Shah RB; Tadros Y; Brummell B; Zhou M
Hum Pathol; 2013 May; 44(5):786-94. PubMed ID: 23158212
[TBL] [Abstract][Full Text] [Related]
36. The value of triple antibody (34βE12 + p63 + AMACR) cocktail stain in radical prostatectomy specimens with crushed surgical margins.
Daoud NA; Li G; Evans AJ; van der Kwast TH
J Clin Pathol; 2012 May; 65(5):437-40. PubMed ID: 22294716
[TBL] [Abstract][Full Text] [Related]
37. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini.
Chastain EC; Oliva IV; Osunkoya AO
Pathology; 2012 Apr; 44(3):199-203. PubMed ID: 22406481
[TBL] [Abstract][Full Text] [Related]
38. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
Epstein JI; Amin MB; Reuter VE; Humphrey PA
Am J Surg Pathol; 2017 Apr; 41(4):e1-e7. PubMed ID: 28177964
[TBL] [Abstract][Full Text] [Related]
39. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody.
Oliai BR; Kahane H; Epstein JI
Am J Surg Pathol; 2002 Sep; 26(9):1151-60. PubMed ID: 12218571
[TBL] [Abstract][Full Text] [Related]
40. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
Herawi M; De Marzo AM; Kristiansen G; Epstein JI
Hum Pathol; 2007 Jan; 38(1):72-8. PubMed ID: 16949907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
